Premium
Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?
Author(s) -
Garber Alan J.
Publication year - 2000
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1046/j.1463-1326.2000.00100.x
Subject(s) - pravastatin , medicine , simvastatin , gemfibrozil , diabetes mellitus , type 2 diabetes , plasminogen activator , endocrinology , insulin resistance , cardiology , cholesterol
Patients with type 2 diabetes are at high risk for coronary heart disease (CHD); frequently, these patients have abnormal lipid profiles, placing them at even greater risk. A syndrome of insulin resistance, hyperinsulinaemia, hypertension, and high levels of fibrinogen and plasminogen activator inhibitor contributes to cardiovascular risk, which is not sufficiently decreased by glycaemic control alone. In several large interventional trials, CHD risk in patients with diabetes was substantially reduced by aggressive lipid‐lowering therapy. In patients with diabetes, CHD, low high‐density lipoprotein levels, and normal low‐density lipoprotein levels, gemfibrozil reduced fatal and non‐fatal CHD events. For lipid‐lowering in patients with diabetes and CHD, pravastatin and simvastatin are the only HMG‐CoA reductase inhibitors shown to reduce fatal and non‐fatal CHD events. Of these, pravastatin has less potential for drug–drug interactions and may be safer to use, particularly for combination therapy with fibric acid derivatives, as may now be important for CHD prevention in mixed dyslipidaemias.